← Eichor
Condition: First Relapse Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: First Relapse

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone
Phase 3 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06561854REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Phase 2 · 18 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT04523428First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
Phase 4 · 1 location(s) · Chinese PLA General Hospital · NCT07101588A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Phase 1 · 17 location(s) · Arvinas Inc. · NCT06393738Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · 24 location(s) · Heidelberg Pharma AG · NCT04879043Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Bengbu Medical University · NCT05192798A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk
Phase 1 · 8 location(s) · GluBio Therapeutics Inc. · NCT06146257A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Phase 1 · 37 location(s) · Aurigene Discovery Technologies Limited · NCT05865002A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Phase 2 · 2 location(s) · Eye & ENT Hospital of Fudan University · NCT05260671Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
Phase 1/Phase 2 · 32 location(s) · Fondazione Italiana Linfomi - ETS · NCT05300282CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
Phase 1 · 4 location(s) · CERo Therapeutics Holdings, Inc. · NCT06834282A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through t
Phase 1 · 20 location(s) · AbbVie · NCT05512390Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling,
Phase N/A · 28 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05772559Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorecta
Phase 1 · 10 location(s) · Rgenta Therapeutics Inc · NCT06462183Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/
Phase 1 · 1 location(s) · Emercell SAS · NCT07044050Long-term Progression of Patients Treated and Monitored for Relapsed or Refractory Ph+ ALL
Phase N/A · 1 location(s) · Group for Research in Adult Acute Lymphoblastic Leukemia · NCT07433400A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequen
Phase 2 · 1 location(s) · Mao Jianhua · NCT07087314A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants
Phase 1/Phase 2 · 8 location(s) · Regeneron Pharmaceuticals · NCT06669247Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor
Phase 1/Phase 2 · 1 location(s) · Universität Münster · NCT05590689A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Phase 1 · 9 location(s) · Janssen Research & Development, LLC · NCT06651229A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With Firs
Phase 2 · 68 location(s) · Pfizer · NCT05748171A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in
Phase 1/Phase 2 · 7 location(s) · Hummingbird Bioscience · NCT06956690Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
NA · 16 location(s) · Centre Leon Berard · NCT04055220A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 13 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06083207Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease
NA · 1 location(s) · Central Hospital, Nancy, France · NCT05733845
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.